The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

New VISMED® MULTI preservative-free multidose dispenser

TRB Chemedica announces the launch of the new VISMED® MULTI fitted with the innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser (OSD) for the treatment of dry eye.

Dry eye patients instil regularly lubricant eye drops, and often for the rest of their life. Most of these patients are elderly and experience difficulties when using preservative-free multidose dispensers, since dispensing systems currently available do not offer overall satisfaction for eye drop delivery.

The OSD squeezable dispenser -the result of more than 10 years of development for the delivery of preservative-free ophthalmic solutions- highlights the following features :
    1) intrinsic intuitiveness of a squeezable container,
    2) user friendliness for all adult age groups due to a low actuation force,
    3) precise and reproducible drop ejection,
    4) ergonomic and pocket size design.

The new VISMED® MULTI, a patented, sterile, hypotonic lubricant eye drops formulation of 0.18 % hyaluronic acid with essential ions calcium, magnesium and potassium, contains 10 ml of solution, equivalent to more than 250 drops and remains sterile for up to 3 months after first use. The worldwide trend to use safe, patient-friendly, cost-effective and preservative-free multidose dispensers such as the OSD system underlines VISMED® MULTI commitment to maintain its status as the gold standard in lubricant eye drops.  




Restoring Synovial Balance in Small Joints

OSTENIL® mini is indicated for the treatment of symptoms of osteoarthritis in small synovial joints such as the carpometacarpal joint of the hand, the ankle joint, the temporomandibular joint and the facet joint of the spine.

OSTENIL® mini is a solution containing hyaluronic acid for injection into the joint cavity. A treatment cycle of 1 to 3 injections of OSTENIL® mini helps restore the normal balance between the breakdown and the production of hyaluronic acid in the affected joint. The net result is a decrease in pain and improvement in joint mobility which may last at least 6 months.

OSTENIL® mini is specifically designed for relief from osteoarthritis in small synovial joints

pdf OSTENIL® MINI instructions for use
pdfOSTENIL® Line Brochure
trb_lock.gif Doctor information

  • English